VIVUS, Inc is a biotechnology business based in the US. VIVUS shares (VVUS) are listed on the NASDAQ and all prices are listed in US Dollars. VIVUS employs 59 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in VIVUS
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VVUS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
VIVUS stock price (NASDAQ: VVUS)Use our graph to track the performance of VVUS stocks over time.
VIVUS shares at a glance
|52-week range||$0.07 - $0.50|
|50-day moving average||$0.12|
|200-day moving average||$0.30|
|Wall St. target price||$1.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.60|
Buy VIVUS shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy VIVUS stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is VIVUS under- or over-valued?
Valuing VIVUS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of VIVUS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
VIVUS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.8 million.
The EBITDA is a measure of a VIVUS's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$73.2 million|
|Gross profit TTM||$43.8 million|
|Return on assets TTM||-2.2%|
|Return on equity TTM||0%|
|Market capitalisation||$8.3 million|
TTM: trailing 12 months
Shorting VIVUS shares
There are currently 3.0 million VIVUS shares held short by investors – that's known as VIVUS's "short interest". This figure is 488.8% up from 510,645 last month.
There are a few different ways that this level of interest in shorting VIVUS shares can be evaluated.
VIVUS's "short interest ratio" (SIR)
VIVUS's "short interest ratio" (SIR) is the quantity of VIVUS shares currently shorted divided by the average quantity of VIVUS shares traded daily (recently around 871468.69565217). VIVUS's SIR currently stands at 3.45. In other words for every 100,000 VIVUS shares traded daily on the market, roughly 3450 shares are currently held short.
However VIVUS's short interest can also be evaluated against the total number of VIVUS shares, or, against the total number of tradable VIVUS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VIVUS's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 VIVUS shares in existence, roughly 170 shares are currently held short) or 0.1704% of the tradable shares (for every 100,000 tradable VIVUS shares, roughly 170 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VIVUS.
Find out more about how you can short VIVUS stock.
VIVUS share dividends
We're not expecting VIVUS to pay a dividend over the next 12 months.
Have VIVUS's shares ever split?
VIVUS's shares were split on a 1:10 basis on 10 September 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VIVUS shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for VIVUS shares which in turn could have impacted VIVUS's share price.
VIVUS share price volatility
Over the last 12 months, VIVUS's shares have ranged in value from as little as $0.0697 up to $0.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VIVUS's is -0.8493. This would suggest that VIVUS's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, VIVUS has bucked the trend.
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc. ; and Alvogen Malta Operations (ROW) Ltd.
VIVUS in the news
Frequently asked questionsWhat percentage of VIVUS is owned by insiders or institutions?
Currently 7.089% of VIVUS shares are held by insiders and 19.065% by institutions. How many people work for VIVUS?
Latest data suggests 59 work at VIVUS. When does the fiscal year end for VIVUS?
VIVUS's fiscal year ends in December. Where is VIVUS based?
VIVUS's address is: 900 East Hamilton Avenue, Campbell, CA, United States, 95008 What is VIVUS's ISIN number?
VIVUS's international securities identification number is: US9285513084 What is VIVUS's CUSIP number?
VIVUS's Committee on Uniform Securities Identification Procedures number is: 928551100
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert